Practice management: GO screening & referral

Article

Current screening and referral methods are thought to be inadequate. But what needs to be done to improve the situation?

Recent Videos
2 experts in this video
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Related Content
A petri dish with a fungal growth in solution sits beneath a microscope. Image credit: ©angellodeco – stock.adobe.com

Plant pathogen Macrophomina phaseolina may be emerging cause of ocular infection in humans

Lynda Charters
January 17th 2025
Article

A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An illustration of a brain, and a superimposed image of molecular structure and genetic helixes, all in green/blue. Image credit: ©kittyfly – stock.adobe.com

RhyGaze announces $86 million in Series A financing for optogenetic vision restoration therapy candidate

Grace Koennecke
January 16th 2025
Article

The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A sign outside the US Food and Drug Administration headquarters. Image credit: ©Tada Images – stock.adobe.com

US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism

Jordana Joy
January 14th 2025
Article

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

A black-and-white photo of a handshake with the logos for Formycon, Klinge Biopharma and Teva over them.

Teva partners with Klinge Biopharma for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)

Hattie Hayes
January 13th 2025
Article

The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy

© 2025 MJH Life Sciences

All rights reserved.